# Catalyst Pharmaceuticals

Type: Company (CPRX)

Source: GetYourBrief — https://getyourbrief.com/entity/catalyst-pharmaceuticals
Canonical HTML page: https://getyourbrief.com/entity/catalyst-pharmaceuticals

## Recent coverage (3 stories, network-wide)

### Root and Catalyst Pharmaceuticals Set for Mid-Week Earnings Showdown
2026-02-24 09:47:49 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Root and Catalyst Pharmaceuticals are scheduled to report quarterly results on Wednesday, offering investors a dual look at high-growth technology and healthcare resilience. Both companies face critical tests regarding their respective expansion strategies and bottom-line improvements in a shifting macroeconomic environment.
Full story: https://getfinancebrief.com/story/root-catalyst-pharmaceuticals-earnings-preview-2026

### Catalyst Pharmaceuticals and Root Set for Pivotal Wednesday Earnings Reports
2026-02-24 09:47:16 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Catalyst Pharmaceuticals (CPRX) and Root (ROOT) are scheduled to release their quarterly financial results this Wednesday, February 25. For Catalyst, the report will be a critical barometer for the commercial uptake of its newly launched DMD treatment, Agamree, and the continued stability of its flagship LEMS therapy, Firdapse.
Full story: https://getbiobrief.com/story/catalyst-pharmaceuticals-root-earnings-preview-2026

### Root and Catalyst Pharmaceuticals Set for Pivotal Wednesday Earnings Reports
2026-02-24 09:43:43 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Root and Catalyst Pharmaceuticals are scheduled to release their quarterly financial results this Wednesday, providing critical data points for the insurtech and orphan drug sectors. Investors are looking for Root's progress toward profitability and Catalyst's continued dominance in the LEMS market.
Full story: https://gethealthbrief.com/story/root-catalyst-pharmaceuticals-earnings-preview-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.